Last reviewed · How we verify
Live attenuated SA 14-14-2 vaccine
A live attenuated Japanese encephalitis virus vaccine that stimulates immune responses against Japanese encephalitis virus through controlled viral replication.
A live attenuated Japanese encephalitis virus vaccine that stimulates immune responses against Japanese encephalitis virus through controlled viral replication. Used for Japanese encephalitis prevention.
At a glance
| Generic name | Live attenuated SA 14-14-2 vaccine |
|---|---|
| Sponsor | PATH |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
SA 14-14-2 is a live attenuated strain of Japanese encephalitis virus (JEV) derived from the wild-type SA 14 strain through serial passage. The vaccine replicates in vaccinated individuals but causes minimal or no disease, triggering both humoral and cellular immune responses that provide protection against natural JEV infection. This approach leverages the immunogenicity of live virus while maintaining safety through attenuation.
Approved indications
- Japanese encephalitis prevention
Common side effects
- Fever
- Injection site reactions
- Myalgia
- Headache
Key clinical trials
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine (PHASE4)
- Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine (PHASE4)
- Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine (PHASE3)
- Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age (PHASE4)
- Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine (PHASE4)
- Immunogenicity of SA 14-14-2 JE Vaccine (PHASE4)
- Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live attenuated SA 14-14-2 vaccine CI brief — competitive landscape report
- Live attenuated SA 14-14-2 vaccine updates RSS · CI watch RSS
- PATH portfolio CI